Opinion|Videos|August 16, 2024
Navigating the Treatment Paradigm for Vitiligo: Efficacy, MOA, and Long-Term Use of FDA-Approved Topical Ruxolitinib
Author(s)Ted Lain, MD, MBA, FAAD
Ted Lain, MD, MBA, FAAD discusses navigating the treatment paradigm for vitiligo.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Related Articles
- A New Perspective on Seborrheic Dermatitis Management
September 11th 2025
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times - Dermatology News and Clinical Insights
1
Beyond the Rash: What Dermatologists Need to Know About the World of Infectious Diseases
2
Nail Pathology in Clinical Practice with Phoebe Rich, MD
3
Adapting to the Age of AI in Clinical Dermatology
4
A Practical Update on Psoriasis and Vitiligo Treatment
5